Alnylam Pharmaceuticals (NASDAQ:ALNY) Raised to “Buy” at StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Friday.

Several other research firms also recently commented on ALNY. Bank of America increased their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Stock Down 1.9 %

Shares of Alnylam Pharmaceuticals stock opened at $237.97 on Friday. The firm has a market cap of $30.69 billion, a price-to-earnings ratio of -90.83 and a beta of 0.32. The stock has a 50-day simple moving average of $258.73 and a 200-day simple moving average of $254.54. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the company earned $1.15 earnings per share. The firm’s quarterly revenue was down 33.3% on a year-over-year basis. On average, equities research analysts expect that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the sale, the chief marketing officer now owns 15,705 shares in the company, valued at $3,941,955. This trade represents a 10.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock valued at $2,540,455 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently bought and sold shares of ALNY. Huntington National Bank raised its stake in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Ashton Thomas Private Wealth LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $26,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $42,000. Finally, True Wealth Design LLC boosted its position in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.